A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease-Reference-Cited by-同舟云学术

A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease

Published:2017-12-04 Issue:1 Volume:32 Page:e13155
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Abu Jawdeh Bassam G.¹²^ORCID,Woodle Ervin Steve³,Leino Abbie D.³,Brailey Paul⁴,Tremblay Simon³,Dorst Tonya³,Abdallah Mouhamad H.⁵,Govil Amit¹,Byczkowski Daniel⁶,Misra Hemant⁶,Abuchowski Abraham⁶,Alloway Rita R.¹

Affiliation:

1. Division of Nephrology; Kidney C.A.R.E. Program; University of Cincinnati College of Medicine; Cincinnati OH USA

2. Cincinnati VA Medical Center; Cincinnati OH USA

3. Division of Transplant Surgery; University of Cincinnati College of Medicine; Cincinnati OH USA

4. Transplant Immunology Division; Hoxworth Blood Center; Cincinnati OH USA

5. Division of Cardiovascular Health and Disease; University of Cincinnati College of Medicine; Cincinnati OH USA

6. Prolong Pharmaceuticals; South Plainfield NJ USA

Funder

Prolong Pharmaceuticals, South Plainfield, NJ

Publisher

Wiley

Subject